Australia markets close in 4 hours 47 minutes
  • ALL ORDS

    6,833.10
    -15.70 (-0.23%)
     
  • ASX 200

    6,620.90
    -15.50 (-0.23%)
     
  • AUD/USD

    0.7361
    +0.0004 (+0.05%)
     
  • OIL

    44.96
    -0.75 (-1.64%)
     
  • GOLD

    1,813.80
    +2.60 (+0.14%)
     
  • BTC-AUD

    23,279.45
    -27.17 (-0.12%)
     
  • CMC Crypto 200

    335.96
    -34.56 (-9.33%)
     
  • AUD/EUR

    0.6176
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0506
    +0.0003 (+0.03%)
     
  • NZX 50

    12,606.01
    +3.99 (+0.03%)
     
  • NASDAQ

    12,152.21
    +72.41 (+0.60%)
     
  • FTSE

    6,362.93
    -28.16 (-0.44%)
     
  • Dow Jones

    29,872.47
    -173.77 (-0.58%)
     
  • DAX

    13,286.57
    -3.23 (-0.02%)
     
  • Hang Seng

    26,819.45
    +149.70 (+0.56%)
     
  • NIKKEI 225

    26,537.31
    0.00 (0.00%)
     

Global Viral Vector and Plasmid DNA Manufacturing Market (2020 to 2030) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

·4-min read

The "Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wide range of immune response types.

Companies Mentioned

  • Brammer Bio

  • Cobra Biologics

  • Cell and Gene Therapy Catapult

  • FinVector Vision Therapies

  • Fujifilm Diosynth Biotechnologies

  • MassBiologics

  • SIRION Biotech

  • Merck KGaA Inc.

  • Thermo Fisher Scientific

  • Uniqure NV

Key Market Trends

Plasmid DNA Segment is Expected to Register Robust Growth.

A plasmid DNA is a small DNA molecule within a cell that is different from the chromosomal DNA, which can replicate independently. Plasmid DNA is currently gaining increasing importance, due to the clinical research applications in gene therapy and genetic vaccination.

  • The demand and therapeutic applications for plasmid DNA (pDNA) have rapidly grown and expanded. Plasmid DNA manufacturing is used for indirect and direct clinical applications. For the direct gene transfer into the human body, good manufacturing practice (GMP)-grade plasmid DNA is being required. The plasmid DNA manufacturing is invariably outsourced to the specialized manufacturers using the in-house platform processes.

  • For instance, in December 2019, Genopis, plasmid DNA manufacturer in San Diego, to Launch GMP Contract Manufacturing Business for plasmid DNA production. Moreover, growing R&D on cancer research owing to the rising burden, increasing demand for DNA therapeutics are expected to fuel the segment growth over the forecast period.

North America Dominates the Market in Terms of Revenue Generated

Currently, North America viral vector and plasmid DNA manufacturing market is witnessing a rapid growth in the market studied, followed by Europe. The United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage. The significant incentives offer through Orphan Drugs Act (United States) and the Orphan Medicinal Products Regulations (European Union) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavour.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases

4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development

4.2.3 Potential Applications in Novel Drug Delivery Approaches

4.3 Market Restraints

4.3.1 High Cost of Gene Therapies

4.3.2 Challenges in Viral Vector Manufacturing Capacity

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Product Type

5.1.1 Plasmid DNA

5.1.2 Viral Vector

5.1.3 Non-viral Vector

5.2 By Application

5.2.1 Cancer

5.2.2 Genetic Disorder

5.2.3 Infectious Disease

5.2.4 Other Diseases

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle-East & Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle-East & Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/pdis2b

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005835/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900